| Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease—a Danish prospective population-based cohort study M Attauabi, A Poulsen, K Theede, N Pedersen, L Larsen, T Jess, ... Journal of Crohn's and Colitis 15 (4), 540-550, 2021 | 77 | 2021 |
| Efficacy of ustekinumab for active perianal fistulizing Crohn’s disease: a systematic review and meta-analysis of the current literature M Attauabi, J Burisch, JB Seidelin Scandinavian Journal of Gastroenterology 56 (1), 53-58, 2021 | 52 | 2021 |
| Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies–a Danish population-based cohort study M Attauabi, JB Seidelin, OK Felding, MD Wewer, LKV Arp, MZ Sarikaya, ... Journal of autoimmunity 118, 102613, 2021 | 43 | 2021 |
| Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease–a systematic review with meta-analysis M Attauabi, GR Madsen, F Bendtsen, JB Seidelin, J Burisch Digestive and Liver Disease 54 (9), 1168-1178, 2022 | 20 | 2022 |
| Systematic review with meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease course of inflammatory bowel diseases M Attauabi, M Zhao, F Bendtsen, J Burisch Inflammatory Bowel Diseases 27 (6), 927-939, 2021 | 20 | 2021 |
| Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases–a Danish prospective population-based cohort study with individual-level data M Attauabi, JF Dahlerup, A Poulsen, MR Hansen, MK Vester-Andersen, ... Journal of Crohn's and Colitis 16 (5), 757-767, 2022 | 16 | 2022 |
| Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology? M Attauabi, J Seidelin, J Burisch Gut 70 (10), 2020-2022, 2021 | 14 | 2021 |
| Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease–a real-world two-center cohort study M Attauabi, I Vind, G Pedersen, F Bendtsen, JB Seidelin, J Burisch European journal of gastroenterology & hepatology 33 (1S), e709-e718, 2021 | 13 | 2021 |
| Effectiveness of third-class biologic treatment in Crohn’s disease: a multi-center retrospective cohort study A Albshesh, J Taylor, EV Savarino, M Truyens, A Armuzzi, DG Ribaldone, ... Journal of clinical medicine 10 (13), 2914, 2021 | 12 | 2021 |
| Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with … M Attauabi, C Höglund, J Fassov, KB Pedersen, HB Hansen, S Wildt, ... Scandinavian Journal of Gastroenterology 56 (9), 1040-1048, 2021 | 11 | 2021 |
| Efficacy of ustekinumab for active perianal fistulizing Crohn disease: a double-center cohort study M Attauabi, J Burisch, JB Seidelin Inflammatory Bowel Diseases 27 (3), e37-e38, 2021 | 10 | 2021 |
| Systematic review with meta-analysis: The impact of cancer treatments on the disease activity of inflammatory bowel diseases S Grimsdottir, M Attauabi, E Kristine Dahl, J Burisch, JB Seidelin Journal of Crohn's and Colitis 17 (7), 1139-1153, 2023 | 8 | 2023 |
| Inflammatory bowel diseases affect the phenotype and disease course of coexisting immune-mediated inflammatory diseases: a systematic review with meta-analysis M Attauabi, MD Wewer, F Bendtsen, JB Seidelin, J Burisch Inflammatory Bowel Diseases 28 (11), 1756-1765, 2022 | 6 | 2022 |
| Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis M Attauabi, EK Dahl, J Burisch, J Gubatan, OH Nielsen, JB Seidelin EClinicalMedicine 57, 2023 | 5 | 2023 |
| Real-life efficacy of tofacitinib in various situations in ulcerative colitis: a retrospective worldwide multicenter collaborative study T Resál, P Bacsur, C Keresztes, A Bálint, R Bor, A Fábián, B Farkas, ... Inflammatory Bowel Diseases, izad135, 2023 | 3 | 2023 |
| Influence of genetics, immunity and the microbiome on the prognosis of inflammatory bowel disease (IBD Prognosis Study): The protocol for a Copenhagen IBD Inception Cohort Study M Attauabi, GR Madsen, F Bendtsen, AV Wewer, R Wilkens, J Ilvemark, ... BMJ open 12 (6), e055779, 2022 | 3 | 2022 |
| A Danish population-based case series of patients with liver cirrhosis and coronavirus disease 2019 M Attauabi, J Burisch, F Bendtsen, N Kimer Scandinavian Journal of Gastroenterology 56 (4), 453-457, 2021 | 3 | 2021 |
| DOP10 Intestinal Ultrasound at IBD diagnosis predicts major disease events–A Copenhagen IBD cohort study GR Madsen, M Attauabi, R Wilkens, J Ilvemark, K Theede, JT Bjerrum, ... Journal of Crohn's and Colitis 16 (Supplement_1), i059-i060, 2022 | 2 | 2022 |
| Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn’s disease M Attauabi, M Zhao, F Bendtsen, J Burisch Therapeutic Advances in Gastroenterology 14, 17562848211004839, 2021 | 2 | 2021 |
| P421 Treatment optimization with vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease–a real-world two-center cohort study M Attauabi, I Vind, G Pedersen, F Bendtsen, J Benedict Seidelin, ... Journal of Crohn's and Colitis 15 (Supplement_1), S425-S426, 2021 | 2 | 2021 |
